← Back to Companies

ADARx Pharmaceuticals

Late-stage clinical biotechnology company developing next-generation RNA therapeutics using proprietary siRNA technology for complement-mediated, genetic, cardiovascular, and central nervous system diseases.

Location
San Diego, California, USA
Categories
rna-therapeutics, biotech, therapeutics, gene-therapy

Notes

ADARx Pharmaceuticals is a late-stage clinical biotechnology company committed to transforming cutting-edge science into next-generation RNA medicines. The company has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing of disease-causing mRNA.

ADARx is advancing multiple clinical programs including ADX-324 for hereditary angioedema (HAE), which entered Phase 3 trials in October 2025 and received FDA Orphan Drug Designation. The company's proprietary PLR™ targeted delivery platform and SPE™ technology enable sustained and precise mRNA silencing.

In May 2025, ADARx announced a major collaboration with AbbVie, receiving $335 million upfront with potential for several billion dollars in milestone payments and royalties to develop next-generation siRNA therapeutics across neuroscience, immunology, and oncology.

Team

  • Zhen Li, Ph.D. - Co-founder, President & Chief Executive Officer
  • Chris Storgard, M.D. - Chief Medical Officer

Additional Research Findings

  • Raised $200 million in oversubscribed Series C financing in August 2023, co-led by Bain Capital Life Sciences and TCGX
  • Lead candidate ADX-324: long-acting siRNA for hereditary angioedema in Phase 3 STOP-HAE trial
  • ADX-038 and multiple other programs in clinical development
  • Proprietary platforms: PLR™ (targeted delivery) and SPE™ (broad technology)
  • Pipeline spans complement-mediated, genetic, cardiovascular, thrombotic, CNS, and metabolic (obesity) diseases
  • AbbVie collaboration (May 2025): $335M upfront, potential billions in milestones
  • In Bain Capital Life Sciences portfolio

Sources